SCHEMBL3569321

SCHEMBL3569321

CN(CCc1ccc2c(S(=O)(=O)c3ccccc3)c[nH]c2c1)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 12/20 0.43
HTR2A P28223 11/20 0.43
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR6 P50406 2/20 0.39
HTR2C P28335 1/20 0.39
POLB P06746 1/20 0.38
SLC6A4 P31645 1/20 0.38
CHRM2 P08172 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD1 P21728 1/20 0.37
HTR1B P28222 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579618 0.84 HTR2A (0.59) SLC6A2HTR2ALMNAHTR6HTR2C
Hydrochloric Acid SCHEMBL3579549 0.83 HTR2A (0.58) SLC6A2HTR2ALMNAHTR6HTR2C
SCHEMBL3572256 0.81 HTR2A (0.61) SLC6A2HTR2AMAPTMEN1KMT2A
SCHEMBL3582410 0.80 SLC6A2 (0.48) SLC6A2HTR2AMAPTHTR6HTR1A
SCHEMBL3569963 0.80 SLC6A2 (0.62) SLC6A2HTR2AALDH1A1LMNASMN1; SMN2
SCHEMBL3574497 0.79 SLC6A2 (0.71) SLC6A2HTR2AALDH1A1MAPTLMNA
SCHEMBL3569941 0.78 SLC6A2 (0.60) SLC6A2HTR2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL3567672 0.78 SLC6A2 (0.63) SLC6A2HTR2AALDH1A1LMNASMN1; SMN2
SCHEMBL14469423 0.78 SLC6A2 (0.48) SLC6A2HTR2AMAPTMEN1KMT2A
SCHEMBL3573119 0.77 HTR6 (0.61) SLC6A2HTR2AHTR6HTR2CHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645752-B2 Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors WYETH LLC (US) 2010-01-12 US claimed
US-20070203120-A1 Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors WYETH (US) 2007-08-30 US claimed
US-7645752-B2 Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors WYETH LLC (US) 2010-01-12 US disclosed
EP-1973876-A2 SULFONYL SUBSTITUTED 1H-INDOLES AS LIGANDS FOR THE 5-HYDROXYTRYPTAMINE RECEPTORS Wyeth (US) 2008-10-01 EP disclosed
US-20070203120-A1 Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors WYETH (US) 2007-08-30 US disclosed
WO-2007084841-A2 SULFONYL SUBSTITUTED 1H-INDOLES AS LIGANDS FOR THE 5-HYDROXYTRYPTAMINE RECEPTORS WYETH (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203120-A1 Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors HTR5A, HTR2C, HTR2A SLC6A2 20/4885HTR2A 3/4885ALDH1A1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.